Imatinib Recruiting Phase 2 Trials for Chronic Myeloid Leukemia (CML) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03906292Frontline Asciminib Combination in Chronic Phase CML
NCT03193281KISS Study: Kinase Inhibition With Sprycel Start up
NCT02001818Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia